• Profile

Efficacy and safety of mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction

Journal of Pediatric Urology Aug 17, 2020

Sager C, Sanmartino M, Burek C, et al. - Researchers investigated the efficacy and safety of mirabegron as adjuvant treatment for patients with refractory neurogenic bladder dysfunction. They studied 37 patients under 18 years of age who underwent Mirabegron. Criteria for inclusion comprised: cases with neurogenic bladder who were under clean intermittent catheterization (CIC) programs and refractory to oral oxybutynin (Group A) and/or onabotulinumtoxinA (Group B). Outcomes revealed significant improvement in the clinical and urodynamic parameters in correlation with Mirabegron treatment. Both groups had a significant rise in bladder capacity and a significant reduction in end-filling detrusor pressure. Attenuation in the intensity of overactivity was noted. According to the records of the voiding diary, administration of Mirabegron led over 70% of the incontinent patients to become dry. No adverse effects were identified.


Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen